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Antiestrogens and selective estrogen receptor modulators (SERMs) such as tamoxifen are effective in controlling the progression of estrogen receptor (ER)-positive breast tumors to more invasive phenotypes. However, over time, many patients acquire resistance totamoxifen. The mechanisms underlying tamoxifen resistance remain elusive. Proline-, glutamic acid-, and leucine-rich protein-1 (PELPI) is a novel ER coactivator that plays a role in both genomic and nongenomic actions of ER. PELPI is predominantly localized in the nucleus in hormonally . responsive tissues, but recent studies suggest that PELPI may be exclusively localized in the cytoplasm in cancer cells. We found that MCF-7 cells engineered to specifically express PELPI in the cytoplasm (PELPl-cyto), exhibited hypersensitivity to estrogen but resistance to tamoxifen. In addition, PELPI-cyto cells exhibited increased association of PELPI with Src, enhanced MAPK activation, and constitutive stimulation of AKT. Altered localization of PELP1 was sufficient to trigger PELPI's interaction with the p85 subunit of P13 kinase and P13K activation. Consistent with these findings, human tumors expressing PELPI in the cytoplasm showed increased AKT activation. Our results suggest that altered localization of coactivators such as PELPI promotes resistance to hormonal therapy, presumably via stimulation of nongenomic estrogen responses such as activation of MAPK and AKT. 14 Recent studies suggest that in addition to its well-studied nuclear functions, ER participates in cytoplasmic and membrane-mediated signaling events (nongenomic signaling). Nongenomic signaling has been linked to the generation of rapid responses to estrogen and generally involves stimulation of the Src, MAPK, P13K and PKC pathways in the cytosol Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1),1 also known as modulator of nongenomic activity of estrogen receptor (MNAR) 2, 3 is a novel ER coregulator that has been implicated in both genomic activity of ER via histone interactions 4 and nongenomic functions of ER via activation of Src/MAPK pathways. Although PELP1 is predominantly localized in the nucleus in hormonally responsive tissues 4 , recent studies suggest that under certain conditions, PELP1 could be exclusively localized in the cytoplasm of a subset of cancer cells 5 . In this study we examined the hypothesis that altered localization of PELP1 may contribute to the hormonal independence and tamoxifen resistance via excessive activation of nongenomic signaling pathways.
BODY
The scope of this proposal is to undertake the following two tasks outlined in the approved statement of work Taskl. Generation of MCF-7 model cells Task2. Testing and characterization of model cells for hormonal responsiveness Task 1. Generation of MCF-7 model cells expressing PELPl-cyto mutant: To examine the functional consequences of cytplasmic localization of ER coactivator PELP1, we generated a mutant of PELP1 (PELPl-cyto) in which the nuclear localization signal was mutated from KKLK to EELE. Using this construct, we generated MCF-7 cells stably expressing PELPl-cyto mutant. To avoid potential clonal variations, we developed two pooled clones. Western blotting showed expression of T7-tagged-PELPl-cyto mutant in these clones. As a control, we have used an earlier characterized wild type PELP1 (PELP1-WT) pooled clone. Confocal scanning analysis showed that PELPl-cyto mutant was localized to the cytoplasm while PELP1-WT was localized to the nucleus. blotting using anti-T7-epitope monoclonal antibody (T7-mAb). Vinculin was used as a loading control. C, MCF-7 cells expressing PELP1-WT or PELPl-cyto were cultured in DCC medium, and fixed in methanol, and the localization T7-tagged PELP1 in these clones was analyzed by confocal microscopy using T7 mAb.
Task 2. Testing and characterization of PELPI-cyto model cells for hormonal responsiveness : Since earlier studies have shown that PELPI interacts with Src kinase, we examined whether altered localization of PELP 1 to the cytoplasmic compartment promotes PELPI interaction with Src. Results from confocal analysis suggested that a substantial amount of PELP 1 was localized in the nuclear compartment in PELP I-WT-expressing cells and that E2 treatment stimulated colocalization of PELPI with Src at the membrane in some cells ( Fig. 2A, top panels). In contrast, in PELP I -cyto-expressing cells, E2 treatment promoted substantial colocalization of PELP I-cyto with Src both at the membrane and in the cytoplasm ( Fig. 2A, bottom panels). Since PELPI interaction with Src has been shown to promote Src activation, these findings raised the possibility that cytoplasmic localization of PELPI might provide an opportunity for PELP 1 to interact with Src, leading to enhanced Src kinase activation. To confirm that PELP I-cyto mutant indeed interact with Src kinase, immunoprecipitation was performed using total cellular lysates from pcDNA and PELPI-cyto mutant expressing cells.
Results showed that PELPI-cyto interacts with Src kinase (Fig. 2B) signalin. When these clones were cultured in DCC serum, PELPI-cyto-expressing clones exhibited increased basal MAPK activity compared to pcDNA-vector-overexpressing clones, and E2 treatment substantially enhanced MAPK activation in PELPI-cyto clones (Fig. 3A) . PELPIcyto expressing cells also showed increased MAPK activity upon tamoxifen treatment compared to pcDNA-expressing clones (Fig. 3B ). To confirm that the increased MAPK activation seen in PELP 1 -cyto clones is due to PELP I -cyto interactions with Src kinase, we have used a specific Src kinase inhibitor PP2. Pretreatment of cells with Src kinase inhibitor PP2 reduced the basal as well as E2 induced MAPK activation seen in the PELPI-cyto clones (Fig. 3C) . (Fig. 3D) .
Fig 3. PELPI Cytoplamic Retention Promotes MAPK activation. AB, pcDNA or PELPi-cyto were treated with E2 (1-9 M) or tamoxifen (10-8 M) , and total lysates were subjected to Western blotting by using a phospho-MAPK antibody. C, pcDNA and PELP1-cyto dones were pretreated with Src kinase inhibitor PP2 for 30 min before the addition of E2 (10-9 M). Activation status of MAPK pathway was analyzed by Western blotting. D, MCF-7 clones expressing pcDNA and PELPI-cyto were cultured in 5% serum, and total lysates were subjected to Western blotting using phospho-ER Serl18.
Cytoplasmic Retention of PELPI Promotes Constitutive Activation of AKT Pathway. Since activation of P13K is another recognized nongenomic signaling of ER, we next examined the functionality of P13K signaling in PELPI-cyto clones using phospho-AKT as a downstream marker of this pathway. Interestingly, PELPI-cyto clones showed excessive constitutive activation of the AKT pathway, which could not be further induced by E2 treatment (Fig. 4A ).
Because the AKT pathway has also been shown to promote tamoxifen resistance, we next examined the status of the AKT pathways in PELP 1 -cyto clones after treating them with tamoxifen. PELPI-cyto expressing cells showed increased AKT activity compared to pcDNAexpressing clones (Fig. 4B ) and the status of already elevated levels of AKT in PELPI-cyto clones was not affected by tamoxifen treatment. Our finding that PELPI-cyto clones exhibit significant constitutive stimulation of the AKT pathway even in the absence of E2 treatment raised the possibility that PELP 1 activation of the AKT pathway may be independent of PELP I's ability to interact with ER. To examine this possibility, we treated pcDNA and PELP 1 -cyto clones with ICI 182,780 for three days to downregulate ER expression and activity. The ICI 182,780 treatment did not affect the levels of constitutive AKT stimulation observed in the PELPI-cyto clones (Fig. 4C) suggesting the increased activation seen in the PELP-cyto clones is independent of ER. We then examined the possibility that increased AKT was due to activation of P13K, an upstream activator of AKT. Treatment of PELP 1-cyto clones with LY294002, a widely used inhibitor of P13K, blocked the constitutive activation of AKT (Fig. 4D ). These findings suggested that cytoplasmic localization of PELP 1 might contribute towards the observed enhanced AKT signaling by activating P13K. We next examined whether PELPI directly interacts with the p85 subunit of P13K and whether the observed altered PELP I localization facilitates constitutive interaction of P13K. Immunoprecipitation of pcDNA, and PELPI-cyto lysates with p85 and T7-antibody showed that PELPI-cyto interacted with the p85 subunit of P13K (Fig. 4E ). Immunoprecipitation and in vitro PI-3 kinase assay also confirmed the noted constitutive activation of the P13K pathway in the PELPI-cyto clones (Fig. 4F ).
Western analysis of PELP 1WT clones also revealed mild activation of AKT however is significantly lower than the magnitude of AKT activation seen in PELPI-cyto clones (Fig. 4G ). PhOSAKTh°SAKT PhOSAKT A, B, pcDNA or PELPl-cyto clones were treated with E2 (10-9 M) or tamoxifen (10-8 M) , and total lysates were subjected to Western blotting by using a phospho-AKT antibody. C, pcDNA and PELPi-cyto clones were treated with or without ICI 182, 780 for 3 days, and total lysates were Western blotted with a phospho-AKT antibody. D, pcDNA and PELPI-cyto clones were treated with or without LY294002 for 60 min, and the total cell lysates were immunoblotted with phospho-AKT antibody. E, pcDNA, and PELPl-cyto cells were cultured in 5% DCC serum, and total cell lysates (2 mg) were subjected to immunoprecipitation by using an antibody that recognizes the p85 subunit of P13K (top panel), or T7 mAb (bottom pane/), which recognizes T7-tagged PELP1. F, pcDNA, PELP1-WT, and PELPi-cyto clones were cultured in 5% DCC serum, and total lysates were subjected to immunoprecipitation using anti-tyrosine mAb PY-20 followed by in vitro P13K assay. G, Total lysates from pcDNA, PELP1-WT, PELPl-cyto clones were subjected to Western blotting using phospho-AKT. H, total lysates from pcDNA or PELPi-cyto clones were subjected to Western blotting using phospho-ER Ser-167 antibody and reprobed with total ER as the loading control.
PELP1 Cytoplasm Retention Promotes Hormonal Independence. To examine the effect of cytoplasmic localization of PELP1 on biological functions, we performed cell proliferation and anchorage independence assays. PELP I-cyto-expressing clones were hypersensitive to E2 treatment compared to parental MCF-7 or pcDNA-vector-expressing clones (Fig. 5A) . Further, PELPI-cyto clones showed an increased ability to form colonies in an anchorage-independent manner compared to pcDNA-expressing cells (Fig. 5B) . Since AKT activation has been shown to promote tamoxifen partial agonist action in breast cancer cells, we repeated these biological assays in the presence or absence of tamoxifen for 7 days. MCF-7 parental and pcDNAexpressing clones showed a 50% reduction in cell number. Interestingly, PELPI-cytoexpressing clones showed resistance to tamoxifen treatment, and the cell number was not altered (Fig. 5C ). In anchorage independence assays, PELPI-cyto-expressing cells exhibited an increased ability to form colonies in the presence of tamoxifen compared to parental or pcDNA clones (Fig. 5D ). These findings suggest a close relationship between PELPI cytoplasmic localization promotes hormonal resistance possibly by excessively activating MAPK and AKT signaling pathways. Tatnoxifen are effectively used to retard the progression of hornonenot by trastuzumob, even in regressing tumors in the TAM group. This dependent breast tumors to more invasive phenotypes. However such observation suggests that trastuzumab's effect on tainrixifen sensitivity therapies have been -cosely linked with an acquircd resistance in breast in this xenograft model does nor occur via the ERK1/2 pathway, tumors and an increased incidence of endometrial cancer, The molecular Together, our results suggest that gefititnib and t-astuzurnab modulate basis of tamoxifen-resistance of breast cancer and -associated the growth of HER2-overexpressing breast tumors through distinct endootetrial cancer remains elusive. In the present study, we tested the mechanisms and that combining such agents., in combination with ERhypothesis that the recently discovered novel ER-regulatory protein targeted therapy is a valid strategy to test in the clinic. ('Iressa' is a proline glutairde acid leueine rich protein (PELPI, also referred to as trademark of the AstraZeneca group of companies.]
MNAR, modulator of nongenonsic activity of estrogen receptor), with functions in both nuclear and cytoplasmic compartments, plays any role in the action of tamoxifen Results: Tamoxi•en-sensitive and -resistant cells expressed similar with advanced disease does not respond to tamoxifen, whereas in those levels of PELPL but exhibited distinct subeellular localization in who respond the tumor ultimately becomes resistant. We aim to assess tamoxifen resistant cells. PELPI deregulation led to a potentiation of whether high-throoghpat gene expression profiling can lead to the agonist activity of tansoxifen in endoinetrial cancer cells, Expression discovery of a new set of markers for therapy resistance that may be of PELPI mutant deficient in activation domain or PELP I siRNA predictive for the type of response to anti-estrogen treatment.
effectively blocked tanoxifen mediated agonist responses. Deregulatim Material and Methods: The study was perforsoed on a series of 70 of PELPI 'expression was observed in both breast and endometrial ER-positive primary breast cancer samples from patients with advanced tumors. linmuoohistological examination of PELPI in: minors revealed disease that shiwed the extreme types of response (objective response, its predominant localization in the cytoplasm as opposed to nuclear n='3, versus progressive disease, n=40, from start of treatment). None localization in the normal tissues. of the patients received adjuvant systemic tatnoxifen therapy. The Disecussion: Our results suggest that altered localization of PELPI! main clinical endpoint of the study is the measurable effect of this MNAR, which could also activate nongenomic signaling, oay be eiidocrine therapy on tumor size and on time until tumor progression., associated with tanioxifen resistance. Since PELPI expression is RNA frnto these breast tumor samples and pool of control cell-lines deregulated in hormonal tumors and because PELYP modulates SERM was isoiated and amplifiead no-hybridized to eDNA micro-arrays, action, we will discuss results implying a role of PELPI/MNAR in containing 18,500 transcripts in the human genome, produced by the hormone resistance.
(This work was supported by Department of NKI/AvL Micro-Array Facility (httpnrsimeroarrays,nki.nl). After Army Grant BC023845) normalization, per sub grid, and a spot quality check, 8600 potentially relevant genes were selected.
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Results: Using a training set of 50 tumors and two distinct binDrug metabolizing en-zymne polymorphisms and outcome in informatics tools (Spotfire and BRB, http:i/tinus.nci.tnih.govsBRB-Aray node-positive bre'st cancer patients: diflerential impact of Tools.htmtl) and a leave-one out approach, a set of 143 overlapping gluta tine brastscane sutyes: genes was found to be differentially expressed (,P<0,0) between glutAthione-S-transferase subtypes. taimoxif~en~responsive' and -resistant breast tumor sape.Ungti DeMichele A, Aplene R, Botbyt J, Got 1, Foulkes A, Siudtmauer E, istoxi'e~repomsie ad -esstat beat tissr amples. Using this Rc-bbeck T University of Peensylvaniis, PhiiodeIphio, P-I gene-set, the cases clustered into two major cluster branches. This 143-gone-set predicted correctly the outcome of response to tamoxifen Background The efficacy of adjuvant chemotherapy for breast cancer treatment in 82% of the eases (with a specificity of 84% and.a ,omay depend, in part, on individual differences in drug metabolizing sensitivity of 80%). This set includes gene associated with celi enzymes (DMEs) . reflecting the balance of phase I (activating) DiMEs proliitratioit (e.g. CFPI), signal transduction (e.g. FTHRl), RNA and/ and phase I1 (detoxifying) DMEs. Polyrnorphisins in genes encoding or DNA binding activity (e.g. NSAPl and TCFLI), extr-sellular matrix cytochrome p450 (CYP) enzymes may increase activation of some (ccg. Usteonectin) and protein serine-threoniac kinases (e.g, PC'UK1). chemotherapeotics (CYP 3A4 *IA*IA or CYP3A5_**Il; Using an add 4 more gene analysis, the classifier set could be optimized' "favorable" phase I DME genotypes) while others may impair activation arid was reduced to 40 genes which correctly predicted the outcome for (CYP3A4_*IB or CYP 3A5 _*3; "unfavorable" phase I DME 96% of the training-cases, This 40-gent predictive set was then used in ganotypes). Meanwhile, improved outcome may be seen with an independent test set of I5 tamoxifen reswtaot tumors, and correctly honsozygous null deletions of the glutathione-S-transferase (GST) genes predicted the outcome of treatment resistanre in 80% of the cases p and e (GSTMI and GSTTI) or point mutations in GST-p (GSTPI; validated. This predictive gene set is currently validated in a larger set "favorable" phase II DME genotypes) due to their inhibition of drug ot breast tumors. metabolism leading to a prolonged half-life of reactive oxygen species. Diarsission: Our data suggest that gene expression profiling caimt"
We hypothesized that combinations of "unfavorable" phase I and phase used to discriminate between breast cancer natietms with an objective 'I DME genotypes would impact recurrence of breast cancer among response to aramuxifen or patients with progressive disease. Further vjatints receiving adjuvant chemotherapy. Material and Methods: validation studies will prove whether this gene-set allows for the I We tested this hypothesis by examining cyp3A4/3A5 and GSTMI, identification of the individual patient who could benefit or fail • GSTTI and GSTPI polymorphisms in a cohort of 80 women with (adjuvant) tanmoxifen therapy.
Z7.-lymph-node positive breast cancer who received high-dose ) cyciophosphamide (1500mg!m2) and thiotepa (200nag/m2) in addition to standard anthracycline -based adjuvant chemotherapy. Genotypes were obtained from subject stem cells using PCR-based methods. We evaluated disease-free survival (DFS).by genotype (individually and in combination) using Kaptan-Meier and Cox propornional hazards models.
Introduction
The estrogen receptor (ER), a ligand-dependent transcription factor that modulates the transcription of a number of genes and contributes to genomic responses, has been implicated in the progression of breast cancer, and this is borne out by the finding that about 60-70% of breast tumors are ER-positive at presentation (1, 2) . Although antiestrogens and selective estrogen receptor modulators (SERMs) are effective in curbing the progression of ER-positive breast tumors to more invasive phenotypes (3), many patients with metastatic breast tumors eventually become resistant to this treatment (4). Several mechanisms have been proposed to explain this resistance to hormonal therapy, including the expression of variant or mutant ER, the ligandindependent activation of ER, the adaptation of tumors to lower concentrations of estrogen, and pharmacological alterations (4, 5) . Emerging data also suggest that ER coregulators play a role in hormonal responsiveness and tumor progression (6, 7). However, the causes of ER coregulatorlinked resistance to hormonal therapy and ways to interfere with this phenomenon remain elusive.
The answer may be in the fact that, in addition to its well-studied nuclear functions, ER also participates in cytoplasmic and membrane-mediated signaling events (nongenomic signaling; 8, 9). Such nongenomic signaling has been linked to rapid responses to estrogen and generally involves the stimulation of the Src kinase, mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase (PI3K), and protein kinase C pathways in the cytosol (10, 11).
Further, ER-activated nongenomic pathways have been shown to modify ER or its coactivators by phosphorylation, resulting in the altered topology of ER and its coregulator proteins and eventually leading to ligand-independent activation or differential responses to SERMs (9, 12).
Other factors implicated in the development and progression of breast cancer are, deregulated epidermal growth factor receptor (EGFR) signaling, and the constitutive activation of cytosolic pathways (MAPK; P13K; AKT) (13) . Now there is also emerging evidence that resistance to endocrine therapies may stem from complex interactions between ER and EGFR signaling components (14) . The phosphorylation of ER and its associated coregulatory proteins has been suggested as one such mechanism by which growth factor signaling contributes to hormonal resistance (15) . However, very little is known about the molecular mechanisms that lead to EGFR-ER crosstalk and the molecular adaptors that facilitate EGFR-ER signaling crosstalk. Generation of PELPI-cyto Cells. PELPI cytoplasmic mutant (PELPI-cyto) lacking nuclear localization signal was generated using a Quick Change kit (Stratagene, La Jolla, CA) by mutating PELPI aa 495KKLK498 to EELE using T7-tagged wild type PELPi as a template. The sequence of the primer used for mutagenesis was 5'-cctagcgcccccgaggagctagagctggatgtg-3'.
MCF-7 cells stably expressing PELP 1 -cyto were generated by transfecting PELP 1 -cyto using FuGENE-6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN). Stable clones were selected using G418 selection (1 mg/ml). Cell Proliferation, Soft-Agar, and Tumorigenesis Assays. For the cell proliferation assays, cells were grown in phenol red-free medium supplemented with 5% DCC serum for 48 hours, and then estrogen or tamoxifen was added. The proliferation rate of the cells was measured by counting them in a Beckman Coulter Counter as previously described (19) . Soft-agar colonygrowth assays were performed as previously described (22) . Briefly, 1 ml of 0.6% DIFCO agar in DMEM supplemented with 5% DCC serum and insulin was layered onto tissue culture plates.
Test cells (lx 104) mixed with 1 ml of 0.36% bactoagar solution in DMEM were layered on top of the 0.6% bactoagar layer. The plates were incubated at 37°C in 5% CO 2 for 21 days. For tumorigenesis studies, 5 x 107 cells were implanted subcutaneously into the mammary fat pads of 8 nude mice as previously described (23) and allowed to grow for 8 weeks. Tumor size was then measured.
Reporter Gene Assay. For reporter gene transient transfections, COS-l cells were cultured for 48 hours in minimal essential medium without phenol red-containing 5% DCC serum. EREluciferase reporter constructs were cotransfected with ER along with or with out pcDNA vector, PELP 1-WT or PELPI-cyto expression plasmids using FuGENE-6 according to the manufacturer's instructions. Twenty-four hours later, cells were treated with EGF for 12 h. Cells were then lysed with passive lysis buffer, and the luciferase assay was performed using a luciferase reporter assay kit (Promega). The total amount of DNA used in the transfections was kept constant by adding a parental vector. Each transfection was carried out in six-well plates in triplicate wells.
Immunofluorescence and Confocal Microscopy. The cellular localization of PELPI was determined using indirect immunofluorescence as described previously (17) .
Statistical Analysis. Statistical analysis was done using Student's t test, and values with p<0.05 were considered statistically significant
Results

PELP1
Localization is altered in a Subset of Breast Tumors. To examine the localization of PELP1 in human breast tumors, we stained 62 breast tumor specimens using a well-characterized PELP I antibody (16, 21; Fig. IA) . The staining intensity was scored in both nuclear and cytoplasmic compartments. Normal breast epithelium (n=8) was used as a control.
All normal breast epithelium stained positively; PELPI staining was strong in the nucleus and modest in the cytoplasm. In tumors, however, PELP I staining intensity and localization was variable. PELPI staining was observed in 38 (61%) of the 62 analyzed tumors. In 22 (58%) of the 38 PELP 1-positive tumors, PELPI was localized in the cytoplasm only; in one tumor (3%), intense nuclear staining was observed, and in 15 tumors (39%), both nuclear and cytoplasmic staining were observed (Table 1) Generation of PELPi-cyto Model Cells. To examine the functional consequences of the cytoplasmic localization of PELP 1, we next generated a mutant of PELP I (PELP I-cyto) in which the nuclear localization signal was mutated from KKLK to EELE (Fig. IB) . Preliminary analysis using confocal microscopy showed that PELP 1 -cyto was predominantly localized in the cytosol. Using this construct, we generated MCF-7 cells that stably expressed PELPI-cyto. To avoid potential clonal variations, we developed two pooled clones. Western blotting showed expression of T7-tagged PELPI-cyto in these clones (Fig. I C) . We used a previously characterized wild-type PELP I (PELP 1-WT) pooled clone as the control (19) . Confocal scanning analysis showed that PELPI-cyto was localized to the cytoplasm while PELPI-WT was localized to the nucleus, as expected (Fig. 1D) . To examine whether the cytoplasmic PELPI observed in the tumors corresponded to the full-length PELP 1, we performed Western blot analysis of the lysates of the tumors that expressed PELP I in the cytoplasm only. Lysates from MCF-7 cells expressing both PELP 1-WT and PELPI-cyto were used as controls. Results showed that PELPI isolated from lysates of the tumors that exclusively expressed PELPI in the cytoplasm migrated in a similar fashion as PELPI-WT and PELPI-cyto that were expressed in MCF-7 cells (Fig. 1E) . These findings suggest that PELPI expressed in the cytoplasm of tumors represents the full-length PELP 1.
Cytoplasmic Retention Enhances PELP1 Interactions with Src Kinase. Recent studies have shown that in addition to its suggested nuclear functions (17) , PELP I participates in nongenomic signaling activities, such as activation of Src (18, 24) . Therefore, we examined whether the localization of PELP I to the cytoplasmic compartment, a physiologic situation existing in a subset of breast tumors, promotes PELP I interaction with Src. Results from confocal microscopy showed that a substantial amount of PELPI was localized in the nuclear compartment of PELP1-WT-expressing cells and that E2 treatment stimulated colocalization of PELP1 with Src at the membrane in some cells ( Fig. 2A, top panels) . In contrast, in PELPIcyto-expressing cells, E2 treatment promoted substantial colocalization of PELP I-cyto with Src both at the membrane and in the cytoplasm ( Fig. 2A, bottom panels) . Another study found that PELPI interaction with Src promotes Src activation (24) ; this raised the possibility that the cytoplasmic localization of PELP I might provide an opportunity for PELP I to interact with Src, thereby leading to enhanced Src kinase activation. To test whether that PELPI-cyto interacts with Src kinase, immunoprecipitation was performed by using total cellular lysates from pcDNA-and PELPI-cyto-expressing cells. Results showed that PELPI-cyto interacts with Src kinase (Fig. 2B, leftpanel) . To confirm that overexpression of PELPI-cyto activates Src kinase, we performed Western blotting with a phospho-specific antibody (phospho-Src Tyr 416) that recognizes activated Src kinase. This showed that PELPI-cyto-expressing cells increased the activation of Src kinase compared with pcDNA-expressing clones (Fig. 2B, rightpanel) . These findings suggest that PELPI cytolocalization promotes PELPI interaction with Src kinase. Since PELP 1-WT functions as a scaffolding protein for the coupling of ER with Src kinase, we then investigated whether PELP 1 -cyto also interacts with ER. The immunoprecipitation of PELP 1-cyto showed that PELPI-cyto could interact with ER (Fig. 2C ).
Cytoplasmic Retention of PELP1 Promotes Activation of the MAPK Pathway. Next we examined whether the interaction we observed between PELP 1 and Src in the PELP 1 -cyto expressing clones leads to the functional activation of MAPK, a well-established downstream endpoint of ER nongenomic signaling (10, 11) . Western blot analysis of cells grown in 5%
serum revealed that PELP 1-WT and PELP I-cyto-expressing cells showed increased activation of the MAPK pathway compared with pcDNA-expressing clones. However, the PELP I-cytoexpressing clones exhibited significantly more MAPK activation than did the PELP1-WT clones (Fig. 2D ). When these clones were cultured in DCC serum, the PELPI-cyto-expressing clones exhibited increased basal MAPK activity compared with pcDNA-vector-overexpressing clones, and E2 treatment substantially enhanced MAPK activation in PELPI-cyto clones (Fig. 2E ).
PELPI-cyto-expressing cells also showed greater MAPK activity in response to tamoxifen treatment than did pcDNA-expressing clones (Fig. 2F) . To confirm that the increased MAPK activation seen in PELP I-cyto clones was due to PELPI-cyto interactions with Src kinase, we pretreated cells with PP2, a specific Src kinase inhibitor. PP2 reduced the basal as well as E2-induced MAPK activation seen in the PELPl-cyto clones (Fig. 2G) . These results suggests that PELPI cytoplasmic localization enhances MAPK activation via its interactions with Src kinase.
Since MAPK activation has been shown to phosphorylate ER on Ser-118, we then examined whether ER was phosphorylated on ER-Ser 118 in the PELP 1 -cyto clones. Western blot analysis of cells grown in 5% serum revealed that PELP I-cyto-expressing clones showed increased ERSerl 18 phosphorylation compared with pcDNA-expressing clones (Fig. 2H) Cytoplasmic Retention of PELP1 Promotes Constitutive Activation of the AKT Pathway. Since the activation of P13K is another recognized nongenomic signaling activator of ER (13), we examined the functionality of P13K signaling in PELP 1 -cyto clones by using phospho-AKT as a downstream marker of this pathway. Interestingly, PELP 1 -cyto clones showed excessive constitutive activation of the AKT pathway that could not be further induced by E2 treatment (Fig. 3A) . Because the AKT pathway has also been shown to promote tamoxifen resistance (25), we examined the status of the AKT pathway in PELPI-cyto clones after treating the clones with tamoxifen. PELPI-cyto-expressing cells showed increased AKT activity compared with pcDNA-expressing clones (Fig. 3B) , and the status of already elevated levels of AKT in PELPI-cyto clones was not affected by tamoxifen. Our finding that PELPI-cyto clones exhibit significant constitutive stimulation of the AKT pathway even in the absence of E2 treatment raised the possibility that PELP1 activation of the AKT pathway might be independent of PELP1 's ability to interact with ER. To examine this possibility, we treated pcDNA and PELP 1 -cyto clones with the antiestrogen ICI 182, 780 for 3 days to down regulate ER expression and activity. The ICI 182, 780 did not affect the levels of constitutive AKT stimulation observed in the PELPI-cyto clones (Fig. 3C) , suggesting that the increased activation seen in the PELPIcyto clones is independent of ER. We then examined the possibility that increased AKT was due to the activation of P13K, an upstream activator of AKT. Treatment of PELP 1 -cyto clones with LY294002, a widely used inhibitor of P13K, blocked the constitutive activation of AKT (Fig.   3D ). These findings suggested that the cytoplasmic localization of PELP I might activate P13K, thereby contributing to enhanced AKT signaling. PELPI-cyto lysates with antibodies p85 and T7 showed that PELPI-cyto interacts with the p85 subunit of P13K (Fig. 3E ). Immunoprecipitation and in vitro P13K assays also confirmed the constitutive activation of the P13K pathway in the PELPI-cyto clones (Fig. 3F) . Western blot analysis of PELP 1-WT clones also revealed mild activation of AKT; however the activation was significantly lower than the magnitude of AKT activation seen in PELP I-cyto clones (Fig. 3G ).
Since AKT activation has been shown to phosphorylate ER on Ser-167, we examined whether ER was phosphorylated in the PELPI-cyto clones. Western blotting using a phospho-specific antibody that recognizes ER Ser-167 confirmed that ER was constitutively phosphorylated on Ser-167 in PELPI-cyto clones (Fig. 3H) . Collectively, these findings suggested that cytoplasmic localization of PELPI promotes constitutive activation of the PI3K-AKT pathway, which can phosphorylate ER.
PELP1 associates with Epidermal Growth Factor Receptor. Previous studies have suggested bidirectional signaling between ER and EGFR pathways and growth factors promotes ER phosphorylation through the PI3K-AKT pathway (13). Since we observed that PELP I interacts with P13K, whose activity is modulated by growth factor signaling, we examined whether PELP 1 interacts with growth factor receptors as well. To determine whether there is physiological evidence of endogenous PELP1-EGFR interactions, we initially examined this in HeLa cells, which abundantly express EGFR and PELPI. HeLa cells were treated with EGF, and the colocalization of PELP1 and EGFR was analyzed by confocal microscopy. Our results showed that EGF stimulation caused a small portion of PELP I to associate with membranous regions, and in some areas, the colocalization of PELPI with EGFR was observed (Fig. 4A, left panel). We next examined whether PELP I -cyto also interacts with EGFR. Confocal microscopy examination of EGF treated PELP I-cyto clones revealed colocalization of PELP 1-cyto with EGFR (Fig. 4A, right panel) . To confirm these results, we performed immunoprecipitation experiments in COS-1 cells, which were treated with or without EGF. Immunoprecipitation of EGFR followed by Western blot analysis with PELPI confirmed that PELPI indeed associates with EGFR upon EGF stimulation (Fig. 4B ).
Since EGF has been shown to promote ligand-independent activation of ER transactivation (Fig. 4C) . Increased basal activity of the ERE reporter in PELPI-cyto transfected cells could be due to the constitutive activation of AKT pathway seen in the PELPIcyto cells. These results suggest that PELP1-WT has a potential to enhance EGF mediated ER transactivation functions and mislocalization of PELP 1 in the cytoplasm can potentially activate ER basal activation by excessively coupling EGFR-PI3K signaling pathways.
Growth factor signaling has been shown to modulate coactivator functions by posttranslation modifications (14) . Since PELP I interacted with EGFR and promoted EGF-mediated ERE transactivation functions, we next examined whether EGF stimulation promotes the phosphorylation ofPELP1. COS-1 cells were transfected with T7-tagged PELPI, and after 48 hours, cells were treated with or without EGF. Total lysates were immunoprecipitated with T7-epitope antibody (Fig. 4D, leftpanel) , and immunoprecipitates were blotted with T7 and phosphotyrosine antibodies. Results showed that EGF promotes tyrosine phosphorylation of PELP 1. Similarly, immunoprecipitation of PELP 1 -cyto from PELP 1 stable clones also showed that EGF promotes tyrosine phosphorylation of PELPI-cyto (Fig. 4D, right panel) .
Since PELPI interacts with ER and promotes E2-mediated nongenomic signaling pathways, we examined whether E2 can promote the tyrosine phosphorylation of PELP 1. MCF-7 cells stably expressing PELP 1-WT were treated with or without E2. Immunoprecipitation experiments showed that E2 also promoted the tyrosine phosphorylation of PELPI (Fig. 4E) . We confirmed these results with confocal microscopic analysis. As shown by phosphotyrosine antibody staining, E2 promoted the membrane localization of PELPI and its colocalization with phosphotyrosine (Fig. 4-) . These results suggest that both EGF and E2 signaling modulate PELP I functions and that the cytoplasmic retention of PELP I excessively promotes the interactions of PELPI with components of the growth factor signaling axis.
PELP1 Cytoplasm Retention Promotes Hormonal Independence. To examine the effect of the cytoplasmic localization of PELPI on biological functions, we performed cell proliferation and anchorage independence assays. Results showed that PELP 1 -cyto-expressing clones were hypersensitive to E2 compared with parental MCF-7-or pcDNA-vector-expressing clones (Fig. 5A) . Further, PELPI-cyto clones showed an increased ability to form colonies in an anchorage-independent manner compared with pcDNA-expressing cells (Fig. 5B) . Since AKT activation has been shown to promote tamoxifen partial agonist action in breast cancer cells, we repeated these biological assays in the presence or absence of tamoxifen for 7 days. MCF-7
parental and pcDNA-expressing clones showed a 50% reduction in cell number. Interestingly, PELPI-cyto-expressing clones showed resistance to tamoxifen, in that the cell number was not altered (Fig. 5C) . In anchorage-independence assays, PELPI-cyto-expressing cells exhibited an increased ability to form colonies in the presence of tamoxifen compared with parental or pcDNA clones (Fig. 5D ). Consistent with these results, PELPI-cyto clones exhibited tumorigenic potential in nude mice, and these tumors also exhibited constitutive activation of the AKT pathway (Fig. 5E ). These findings suggest that a close relationship exists between PELP I cytoplasmic localization, AKT activation, and tumorigenesis.
Discussion
In this study, we observed that the localization of the ER coactivator PELPI is altered in a subset of breast tumors. Specifically, model cells that mimic PELPI localization in tumors, we observed that the cytoplasmic localization of PELP1 promotes its interactions with EGFR, Src, and P13K, thereby leading to the activation of the MAPK and AKT pathways. In addition, the altered localization of PELPI promoted hypersensitivity to estrogen and anchorage independence. Our results thus indicate that the ER coactivator PELPI may contribute to tumorigenesis in breast tumors by serving as a molecular adaptor between EGFR-ER pathways and by promoting excessive crosstalk between these pathways.
The altered localization of the ER coactivator PELP 1, which has the potential to stimulate nongenomic ER functions (18, 24) , may alter the ratio of genomic and nongenomic signaling in breast cancer cells and thus might promote hormonal independence by modulating ERtransactivating functions and SERM actions. As our study and other studies indicate, PELP 1 expression is deregulated in breast and endometrial cancers (16, 21) ; therefore, the altered localization of PELPI is expected to contribute toward the excessive activation of the MAPK and P13K-AKT pathways, leading to follow-up modifications of ER. Such modifications of the ER pathway may lead to the activation of ER target genes in a ligand-independent manner.
Alternatively, the modified ER may allow the recruitment of a different set of coregulator proteins, and thus may exhibit resistance to hormonal therapy. In our study, the cytoplasmic localization of PELP1 promoted increased activation of MAPK, leading to enhanced ER-Serl 18 phosphorylation. Similarly, these clones also exhibited constitutive activation of the AKT pathway, which was not further induced by E2. Therefore, the enhanced E2-mediated growth and anchorage independence seen in these clones is likely to be caused by excessive activation of the MAPK pathway, while tamoxifen-mediated resistance could be due to the cumulative effect of the activation of the MAPK and AKT pathways, which leads to the modification of ER and its associated proteins as well as the activation of downstream pathways by activated MAPK and AKT.
ER coregulatory proteins have been suggested to play a role in the generally observed tissue-specific effects of tamoxifen (29, 30) . However, these ER coregulators are targeted by excessive ER-HER2 crosstalk leading to hormonal resistance in a subset of breast tumors (15) .
High levels of the ER coactivator AIB 1 and HER2 in breast cancer contribute to tamoxifen resistance (31) . Our findings that PELPI interacts with EGFR, and that PELPI has the ability to enhance EGF-mediated ER transactivation functions suggest that PELP I potentiates growth factor receptor-mediated hormonal resistance in a subset of tumors that have deregulated growth factor signaling.
Growth factor signaling promotes ER phosphorylation (both Ser and tyrosine; 14, 32).
Recent evidence suggests that ER coactivators; in addition to ER, are targets of growth factor signaling (33) . Growth factor-mediated activation of nongenomic pathways and phosphorylation of ER and ER-coregulatory proteins have been shown to have a role in tamoxifen resistance (28, 34) . Our findings that PELPI enhances tamoxifen resistance and that EGF promotes the phosphorylation of PELP1 suggest that possibility that growth factor-mediated posttranslational modification of PELP I may play an important role in PELP 1-mediated hormonal resistance functions.
Activation of the PI3K-AKT pathway has been shown to be an essential step in the estrogenic action of growth factors (35) . Previous studies also demonstrated that forced expression of constitutively active AKT in MCF-7 cells promotes E2-independent growth as well as tamoxifen response (25) . A recent study found that overexpression of the ER coactivator AIB I promoted high tumor incidence, which is associated with the activation of the PI3K-AKT pathway (36) . Our findings suggest that cytoplasmic localization of PELPI plays a role in tamoxifen resistance and that the ability of PELPI to modulate the PI3K-AKT pathways may represent one mechanism by which PELPI-cyto cells develop resistance to hormonal treatment.
Further, our analysis of human breast tissues provided the proof-of-principle that PELP I localization is altered in a subset of human breast tumors.
Our results suggest that the cytoplasmic localization of PELP I may play a role in the constitutive activation of AKT in tumor cells. Our findings also suggest the existence of a close relationship between cytoplasmic PELPI localization and increased nongenomic signaling.
Additionally, our findings suggest that the cytoplasmic localization of PELP I might be sufficient to promote tumorigenic phenotypes and hormonal independence. Further, the ability ofPELP1-cyto cells to form tumors in nude mice and the presence of increased AKT signaling in these tumors also supports the potential role of PELPI localization in tumorigenesis. Since these tumors were formed in the absence of estrogen pellet implantation, PELP 1-mediated constitutive activation of the AKT pathway rather than the MAPK pathway might play a role in PELPI-cytomediated in vivo tumorigenic functions. It will be interesting to discover the mechanisms by which PELPI localization is altered in pathologic conditions. Since cytoplasmic PELPI observed in the tumors migrated in a similar fashion as PELP-WT, it is likely that it represents a fulllength protein and that its deregulation in localization could be because of posttranslational modifications or mutations that affect its localization to the nuclear compartment. Our future studies will be directed at identifying the mechanisms of PELP1 deregulation, including possible posttranslational modifications / mutations in tumors.
In summary, our results suggest that the localization of ER coactivators such as PELP I
could activate nongenomic signals and may play an important role in the hormonal responses of ER-positive cancer cells (Fig. 5F) . Furthermore, the ability of PELP1 to activate MAPK and AKT signaling pathways, its potential to enhance tamoxifen resistance, and its distinct localization in a subset of breast tumors suggest that PELPI plays a role in the biology of a subset of breast cancers and that its deregulation might contribute to hormonal independence. Expression of T7-tagged PELP1-cyto was analyzed by Western blotting using anti-T7-epitope monoclonal antibody (T7-mAb). Vinculin was used as a loading control. D, MCF-7 cells expressing PELP1-WT or PELPI-cyto were cultured in DCC medium and fixed in methanol.
The localization of T7-tagged PELPI in these clones was analyzed by confocal microscopy using T7 mAb. E, Total lysates obtained from breast tumors or MCF-7 clones that stably express PELP 1 -WT and PELP 1 -cyto were analyzed by Western blotting using PELP 1 antibody (top) and subsequently reprobed with an actin antibody, which served as a loading control (bottom). Activation status of MAPK pathway was analyzed by Western blotting. H, MCF-7 clones expressing pcDNA and PELP I-cyto were cultured in 5% serum, and total lysates were subjected to Western blotting using phospho-ER Seri 18 and subsequently reprobed with total ER. or tamoxifen (10-8 M), and total lysates were subjected to Western blotting by using a phospho-AKT antibody. Blots were stripped and reprobed with total AKT as a loading control. C, pcDNA and PELP1-cyto clones were treated with or without ICI 182, 780 for 3 days, and total lysates were Western blotted with a phospho-AKT antibody. Blot was reprobed with total AKT and ER antibody. D, pcDNA and PELPI-cyto clones were treated with or without LY294002 for 60 min, and the total cell lysates were immunoblotted with phospho-AKT antibody. E, pcDNA, and PELPI-cyto cells were cultured in 5% DCC serum, and total cell lysates (2 mg) were subjected to immunoprecipitation by using an antibody that recognizes the p85 subunit of P13K
(top panel), or T7 mAb (bottom panel), which recognizes T7-tagged PELP 1. F, pcDNA, PELP 1-WT, and PELPI-cyto clones were cultured in 5% DCC serum, and total lysates were subjected to immunoprecipitation by using anti-tyrosine mAb PY-20 followed by in vitro P13K assay. G, MCF-7 clones expressing pcDNA, PELP1-WT, PELPI-cyto were cultured in 5% DCC serum, and total lysates were subjected to Western blotting using phospho-AKT followed by total AKT as the loading control. H, pcDNA or PELPI-cyto clones were cultured in 5% DCC serum and total lysates were subjected to Western blotting using phospho-ER Ser-167 antibody and reprobed with total ER as the loading control. E, Nude mice were injected in the mammary fat pad with 5 X 10 7 MCF-7 cells that stably express either pcDNA or PELPI-cyto, and tumor growth was measured after 8 weeks.
Morphology of tumor was evaluated by hematoxylin-eosin staining, and activation of AKT pathway in the tumors was confirmed by immunohistochemistry with a phospho-AKT antibody.
F, Model for PELP I regulation of ER functions. Cytoplasmic localization of PELP I promotes its interactions with EGFR, Src kinase and PI3K, thus leading to the activation of nongenomic pathways including MAPK and AKT. Such excessive activation of nongenomic pathways promotes hypersensitivity and tamoxifen resistance, which could in part be due to the modification of ER phosphorylation. PELP1 serves as an adaptor protein because it interacts with growth factor receptors, signaling kinases, and nuclear receptors, its deregulation may perturb ER signaling network toward tumnorigenesis. 
